EP1137646A1 - Derivative of paroxetine - Google Patents

Derivative of paroxetine

Info

Publication number
EP1137646A1
EP1137646A1 EP99961195A EP99961195A EP1137646A1 EP 1137646 A1 EP1137646 A1 EP 1137646A1 EP 99961195 A EP99961195 A EP 99961195A EP 99961195 A EP99961195 A EP 99961195A EP 1137646 A1 EP1137646 A1 EP 1137646A1
Authority
EP
European Patent Office
Prior art keywords
compound
paroxetine
salt
acid
disorders
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP99961195A
Other languages
German (de)
French (fr)
Inventor
David Alan c/o SmithKline Beecham Pharma. JONES
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SmithKline Beecham Ltd
Original Assignee
SmithKline Beecham Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SmithKline Beecham Ltd filed Critical SmithKline Beecham Ltd
Publication of EP1137646A1 publication Critical patent/EP1137646A1/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents

Definitions

  • the present invention relates to a novel compound, to processes for preparing it and to its use in treating medical disorders.
  • the present invention relates to a novel derivative of paroxetine.
  • This invention relates to a novel derivative of paroxetine.
  • the compound of this invention may exist in the free acid form as shown in formula (1) or as the corresponding zwitterion. Both forms are part of this invention.
  • the compound of formula (1) may also exist as salts for example with alkali metals or amines, or addition salts with strong acids. Suitable salts include those with alkali metals, preferably sodium, potassium or lithium, or with a mineral acid, for example hydrochloric acid, or sulphonic acid. Amine salts may include salts with paroxetine itself. Also the compound of formula (1) may exist as a mono- or di-salt, or as a mixed salt.
  • a particularly important salt is the 1 :1 (by mole) salt with paroxetine.
  • Compounds of structure (1) have a chiral centre on the piperidine nitrogen substituent as well as the two chiral centres on the piperidine ring, so may exist in two forms. These forms may be separated by crystallisation or chromatography, optionally in the form of a salt, for example a salt with an optically active base.
  • the present invention also provides a method for the preparation of compounds of formula (1) by the addition reaction of paroxetine (as the free base) to maleic acid.
  • the procedure may be carried out at elevated temperature in an appropriate solvent.
  • solvents suitable for the addition reaction are polar aprotic solvents, for example N.N-dimethylformamide, alcohols such as ethanol and isopropanol, and esters such as ethyl acetate, and hydrocarbons such as toluene.
  • polar aprotic solvents for example N.N-dimethylformamide
  • alcohols such as ethanol and isopropanol
  • esters such as ethyl acetate
  • hydrocarbons such as toluene.
  • the reaction of paroxetine with maleic acid tends to result in the recovery of the paroxetine salt of the compound of formula (1) rather than the free acid. Accordingly the free acid is suitably obtained by preparing the salt and treating the salt to recover the acid.
  • the paroxetine salt of compound (1) may conveniently be prepared by contacting paroxetine free base with maleic acid in a suitable solvent, for example toluene, ethyl acetate or 2-butanol, preferably at elevated temperature, for example above 60°C.
  • a suitable solvent for example toluene, ethyl acetate or 2-butanol, preferably at elevated temperature, for example above 60°C.
  • the paroxetine salt of compound (1) may be isolated by crystallisation, and may be purified by a hot slurry, for example at reflux temperature in an appropriate solvent, for example an ester such as ethyl acetate, an alcohol such as propan-2-ol, or a ketone such as acetone.
  • the paroxetine salt of compound (1) may also be prepared from paroxetine maleate (1 :1) salt by heating in an appropriate solvent, preferably butan-2-ol.
  • Compound (1) may be isolated from its paroxetine salt by acidification with 1 equivalent of acid, for example hydrochloric acid.
  • compound (1) may be prepared by addition of 1 molar equivalent of hydrogen chloride in propan-2-ol to a suspension of the paroxetine salt of compound (1) in propan-2-ol with or without heating, and isolated as the free acid by crystallisation from the reaction medium by the addition of water and acetone.
  • compound (1) free acid may be prepared from the isolated paroxetine salt by treatment with 1 equivalent of hydrochloric acid in acetone followed by crystallisation from the medium.
  • salts of compound (1) for example mono sodium or mono lithium salts may be prepared by reaction of compound (1) with 1 equivalent of base, for example sodium or lithium hydroxide respectively.
  • Another class of salts of compound (1) may be formed by reaction with 2 equivalents of strong base, such as for example the disodium or dipotassium salt.
  • Paroxetine free base may be prepared according to the procedures generally outlined in US Patent No 4,007,196 and EP-B-0 223403. Maleic acid is commercially available.
  • Compound (1) and its salts of this invention are anticipated to be useful to treat and prevent the following disorders:
  • the Disorders are hereinafter referred to as "the Disorders”.
  • the present invention further provides a method for treating and/or preventing any one or more of the Disorders by administering an effective and/or prophylactic amount of a compound of the invention to a sufferer in need thereof.
  • the present invention further provides a pharmaceutical composition for use in the treatment and/or prevention of any one or more of the Disorders which comprises an admixture of a compound of the invention with a pharmaceutically acceptable carrier.
  • the present invention also provides the use of a compound of the invention for treating and/or preventing any one or more of the Disorders.
  • the present invention also provides the use of a compound of the invention in the manufacture of a medicament for treating and/or preventing any one or more of the Disorders.
  • the present invention is applied to the treatment of depression, OCD and panic.
  • compositions containing a compound of this invention may be formulated for administration by any route, and examples are oral, sub-lingual, rectal, topical, parenteral, intravenous or intramuscular administration. Preparations may, if desired, be designed to give slow release of the paroxetine derivative or salt.
  • the medicaments may, for example, be in the form of tablets, capsules, sachets, vials, powders, granules, lozenges, reconstitutable powders, or liquid preparations, for example solutions or suspensions, or suppositories.
  • the composition is usually presented as a unit dose composition containing from 1 to 200mg of active ingredient calculated on a free base basis, more usually from 5 to lOOmg, for example 10 to 50mg such as 10, 12.5, 15, 20, 25, 30 or 40mg by a human patient. Most preferably unit doses contain 20mg of active ingredient calculated on a free base basis. Such a composition is normally taken from 1 to 6 times daily, for example 2, 3 or 4 times daily so that the total amount of active agent administered is within the range 5 to 400mg of active ingredient calculated on a free base basis. Most preferably the unit dose is taken once a day.
  • Preferred unit dosage forms include tablets or capsules.
  • compositions of this invention may be formulated by conventional methods of admixture such as blending, filling and compressing.
  • Suitable carriers for use in this invention include a diluent, a binder, a disintegrant, a colouring agent, a flavouring agent and/or preservative. These agents may be utilised in conventional manner, for example in a manner similar to that already used for marketed anti-depressant agents.
  • compositions include those described EP-B-0223403, and US 4,007,196 in which the products of the present invention may be used as the active ingredients.
  • paroxetine base and maleic acid 0.5 mole equivalents
  • ethyl acetate 5 volumes
  • the crystalline solid which formed was collected by filtration, washed with ethyl acetate and dried under vacuum to give 1 -N-(3S,4R)- trans-(4'-fluorophenyl)-3-[3',4'-methylenedioxymethylphenoxymethyl] piperidinyl butandioic acid as the paroxetine salt.
  • N-phenyloxycarbonyl paroxetine (5.0 kg ), potassium hydroxide flake (4.5 kg ) and toluene (75.0 litres) were heated to reflux under a nitrogen atmosphere. After stirring for 4 hours at reflux the contents of the reactor were allowed to cool to room temperature. Water (50 litres) was added and the mixture stirred for 30 minutes and then allowed to settle. The lower aqueous layer was drained from the reactor and the toluene layer heated to reflux and dried in a Dean and Stark apparatus. Toluene (10 litres) was added and approximately 10 litres of the solvent was removed by distillation. The remaining solution was cooled to approximately 90-95°C and solid maleic acid (1.04 kg) was added with vigorous stirring.
  • IR ⁇ maxcm 1 ) 1608, 1512, 1376, 1298, 1234, 1181, 1143, 1106, 1033, 930, 831,
  • Example 4 Preparation of l-N-(3S,4R)-trans-(4-fluorophenyl)-3-[3,4- methylenedioxymethyloxymethyl] piperidinyl butandioic acid.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Addiction (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Child & Adolescent Psychology (AREA)
  • Anesthesiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Nutrition Science (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Compounds of Formula (1) and alkali metal and amine and acid addition salts thereof are useful in the treatment of CNS disorders.

Description

DERIVATIVE OF PAROXETINE
The present invention relates to a novel compound, to processes for preparing it and to its use in treating medical disorders. In particular the present invention relates to a novel derivative of paroxetine.
Pharmaceutical products with antidepressant and anti-Parkinson properties are described in US-A-3912743 and US-A-4007196. An especially important compound among those disclosed is paroxetine, the -)trans isomer of 4-(4'-fluorophenyl)-3-(3',4'-methylenedioxy- phenoxymethyl)-piperidine. This compound is used in therapy as the hydrochloride salt for the treatment and prophylaxis of mter alia depression, obsessive compulsive disorder (OCD) and panic.
This invention relates to a novel derivative of paroxetine.
According to the present invention there is provided a compound of formula (1)
N
C02H
C02H
(1) (2-[(3S,4R)-trans-4-(4*-fluorophenyl)-3-(3",4M- methylendioxyphenoxymethyl)piperidin-l-yl]butan-l ,4-dioic acid)
The compound of this invention may exist in the free acid form as shown in formula (1) or as the corresponding zwitterion. Both forms are part of this invention.
The compound of formula (1) may also exist as salts for example with alkali metals or amines, or addition salts with strong acids. Suitable salts include those with alkali metals, preferably sodium, potassium or lithium, or with a mineral acid, for example hydrochloric acid, or sulphonic acid. Amine salts may include salts with paroxetine itself. Also the compound of formula (1) may exist as a mono- or di-salt, or as a mixed salt.
A particularly important salt is the 1 :1 (by mole) salt with paroxetine.
Compounds of structure (1) have a chiral centre on the piperidine nitrogen substituent as well as the two chiral centres on the piperidine ring, so may exist in two forms. These forms may be separated by crystallisation or chromatography, optionally in the form of a salt, for example a salt with an optically active base.
The individual isomers, and mixtures thereof, of the compounds of formula (1) and the above described salts are all within the scope of this invention.
The present invention also provides a method for the preparation of compounds of formula (1) by the addition reaction of paroxetine (as the free base) to maleic acid. The procedure may be carried out at elevated temperature in an appropriate solvent.
Among solvents suitable for the addition reaction are polar aprotic solvents, for example N.N-dimethylformamide, alcohols such as ethanol and isopropanol, and esters such as ethyl acetate, and hydrocarbons such as toluene.
The reaction of paroxetine with maleic acid tends to result in the recovery of the paroxetine salt of the compound of formula (1) rather than the free acid. Accordingly the free acid is suitably obtained by preparing the salt and treating the salt to recover the acid.
The paroxetine salt of compound (1) may conveniently be prepared by contacting paroxetine free base with maleic acid in a suitable solvent, for example toluene, ethyl acetate or 2-butanol, preferably at elevated temperature, for example above 60°C. The paroxetine salt of compound (1) may be isolated by crystallisation, and may be purified by a hot slurry, for example at reflux temperature in an appropriate solvent, for example an ester such as ethyl acetate, an alcohol such as propan-2-ol, or a ketone such as acetone. The paroxetine salt of compound (1) may also be prepared from paroxetine maleate (1 :1) salt by heating in an appropriate solvent, preferably butan-2-ol. Compound (1) may be isolated from its paroxetine salt by acidification with 1 equivalent of acid, for example hydrochloric acid. Hence compound (1) may be prepared by addition of 1 molar equivalent of hydrogen chloride in propan-2-ol to a suspension of the paroxetine salt of compound (1) in propan-2-ol with or without heating, and isolated as the free acid by crystallisation from the reaction medium by the addition of water and acetone. Alternatively, compound (1) free acid may be prepared from the isolated paroxetine salt by treatment with 1 equivalent of hydrochloric acid in acetone followed by crystallisation from the medium.
Alternatively, neutralisation of the paroxetine salt of compound (1) with 1 molar equivalent of an acid such as hydrochloric acid followed by evaporation or lyophilisation, produces a solid mixture of the salt of paroxetine with the acid, for example paroxetine hydrochloride, and compound (1), and this two component pharmaceutical salt is also included within the scope of this invention.
Other salts of compound (1), for example mono sodium or mono lithium salts may be prepared by reaction of compound (1) with 1 equivalent of base, for example sodium or lithium hydroxide respectively.
Another class of salts of compound (1) may be formed by reaction with 2 equivalents of strong base, such as for example the disodium or dipotassium salt.
Paroxetine free base may be prepared according to the procedures generally outlined in US Patent No 4,007,196 and EP-B-0 223403. Maleic acid is commercially available.
Compound (1) and its salts of this invention are anticipated to be useful to treat and prevent the following disorders:
Alcoholism Anxiety
Depression Obsessive Compulsive Disorder
Panic Disorder Chronic Pain
Obesity Senile Dementia
Migraine Bulimia
Anorexia Social Phobia
Pre-Menstrual Syndrome (PMS) Adolescent Depression
Trichotillomania Dysthymia Substance Abuse
These disorders are hereinafter referred to as "the Disorders".
Accordingly, the present invention further provides a method for treating and/or preventing any one or more of the Disorders by administering an effective and/or prophylactic amount of a compound of the invention to a sufferer in need thereof.
The present invention further provides a pharmaceutical composition for use in the treatment and/or prevention of any one or more of the Disorders which comprises an admixture of a compound of the invention with a pharmaceutically acceptable carrier.
The present invention also provides the use of a compound of the invention for treating and/or preventing any one or more of the Disorders.
The present invention also provides the use of a compound of the invention in the manufacture of a medicament for treating and/or preventing any one or more of the Disorders.
Most suitably the present invention is applied to the treatment of depression, OCD and panic.
Compositions containing a compound of this invention may be formulated for administration by any route, and examples are oral, sub-lingual, rectal, topical, parenteral, intravenous or intramuscular administration. Preparations may, if desired, be designed to give slow release of the paroxetine derivative or salt.
The medicaments may, for example, be in the form of tablets, capsules, sachets, vials, powders, granules, lozenges, reconstitutable powders, or liquid preparations, for example solutions or suspensions, or suppositories.
The composition is usually presented as a unit dose composition containing from 1 to 200mg of active ingredient calculated on a free base basis, more usually from 5 to lOOmg, for example 10 to 50mg such as 10, 12.5, 15, 20, 25, 30 or 40mg by a human patient. Most preferably unit doses contain 20mg of active ingredient calculated on a free base basis. Such a composition is normally taken from 1 to 6 times daily, for example 2, 3 or 4 times daily so that the total amount of active agent administered is within the range 5 to 400mg of active ingredient calculated on a free base basis. Most preferably the unit dose is taken once a day.
Preferred unit dosage forms include tablets or capsules.
The compositions of this invention may be formulated by conventional methods of admixture such as blending, filling and compressing.
Suitable carriers for use in this invention include a diluent, a binder, a disintegrant, a colouring agent, a flavouring agent and/or preservative. These agents may be utilised in conventional manner, for example in a manner similar to that already used for marketed anti-depressant agents.
Specific examples of pharmaceutical compositions include those described EP-B-0223403, and US 4,007,196 in which the products of the present invention may be used as the active ingredients.
The following Examples illustrate the invention.
Example 1
A mixture of paroxetine base and maleic acid (0.5 mole equivalents) in ethyl acetate (5 volumes) was stirred and heated to reflux to give a clear solution, then cooled to room temperature. The crystalline solid which formed was collected by filtration, washed with ethyl acetate and dried under vacuum to give 1 -N-(3S,4R)- trans-(4'-fluorophenyl)-3-[3',4'-methylenedioxymethylphenoxymethyl] piperidinyl butandioic acid as the paroxetine salt.
Example 2
N-phenyloxycarbonyl paroxetine (5.0 kg ), potassium hydroxide flake (4.5 kg ) and toluene (75.0 litres) were heated to reflux under a nitrogen atmosphere. After stirring for 4 hours at reflux the contents of the reactor were allowed to cool to room temperature. Water (50 litres) was added and the mixture stirred for 30 minutes and then allowed to settle. The lower aqueous layer was drained from the reactor and the toluene layer heated to reflux and dried in a Dean and Stark apparatus. Toluene (10 litres) was added and approximately 10 litres of the solvent was removed by distillation. The remaining solution was cooled to approximately 90-95°C and solid maleic acid (1.04 kg) was added with vigorous stirring. The temperature was held at 40°C for two hours to allow for the bulk of the crystallisation to occur, then the product was filtered and dried to give 1-N- (3S,4R)-trans-(4'-fluorophenyl)-3-[3',4'-methylenedioxymethylphenoxymethyl] piperidinyl butandioic acid (3.7 kg, approximately 30% pure).
A portion of this solid (340 g) was suspended in ethyl acetate (1.5 litres) and heated at reflux for 1 hour. The suspension was cooled slightly and the solid collected by filtration. The solid was washed with ethyl acetate and dried under vacuum to give 50.56g of pure l-N-(3S,4R)-trans-(4'-fluorophenyl)-3-[3',4'- methylenedioxymethylphenoxymethyl] piperidinyl butandioic acid as the 1 : 1 paroxetine salt, as a white crystalline solid.
Characterisation:
IR^maxcm"1) 1608, 1512, 1376, 1298, 1234, 1181, 1143, 1106, 1033, 930, 831,
780,721,542.
MS (positive ion electrospray) 330 (M+H)+ (100%), 446 (M+H)+ (15%) (negative ion electrospray) 889 (2M-H)+ (100%). Melting point 185-191°C.
Example 3.
Preparation of l-N-(3S,4R)-trans-(4-fluorophenyl)-3-[3,4- methylenedioxymethyloxymethyl] piperidinyl butandioic acid paroxetine salt.
Maleic acid (0.176 g) was added to a solution of paroxetine free base (0.5 g) in toluene at 90-95°C with rapid stirring. The reaction mixture was stirred at this temperature for 1 hour then cooled to 40-50°C and the crystalline product that formed isolated by filtration. The solid was re-suspended in hot ethyl acetate and stirred for 1 hour. The hot suspension was filtered to give the title compound as a white solid.
Example 4 Preparation of l-N-(3S,4R)-trans-(4-fluorophenyl)-3-[3,4- methylenedioxymethyloxymethyl] piperidinyl butandioic acid. A suspension of l-N-(3S,4R)-trans-(4-fluorophenyl)-3-[3,4- methylenedioxymethyloxymethyl] piperidinyl butandioic acid paroxetine salt (5.06 g) in propan-2-ol (50 ml) was treated with a solution of hydrogen chloride in propan-2-ol (6N, 1.3 ml). The reaction mixture was briefly heated to reflux to form a clear solution, then cooled to room temperature, diluted with acetone (5 ml) and then water (150 ml). The resulting cloudy solution was stirred and scratched to induce crystallisation. Filtration and drying gave the title compound as a white crystalline solid(1.43 g).
Characterisation:
MS (positive ion electrospray) 330 (M+H)+(90%), 446 (M+H)+ (100%).
(negative ion electrospray) 444 (M-H)+(60%), 889 (2M-H)+ (100%).
Example 5
A stirred suspension of l-N-(3S,4R)-trans-(4-fluorophenyl)-3-[3,4- methylenedioxymethyloxymethyl] piperidinyl butandioic acid 1 : 1 paroxetine salt (2.60 g) in acetone (50 ml) was treated with a solution of aqueous hydrochloric acid (0.5 ml, 5 molar) and the mixture was stirred vigorously at room temperature. Water (15 ml) was added to give a cloudy solution which was seeded with 1-N- (3S,4R)-trans-(4-fluorophenyl)-3-[3,4-methylenedioxymethyloxymethyl] piperidinyl butandioic acid. Further stirring and scratching induced crystallisation of l-N-(3S,4R)-trans-(4-fluorophenyl)-3-[3,4-methylenedioxymethyloxymethyl] piperidinyl butandioic acid as a white crystalline solid (0.62 g).

Claims

A compound of formula (1)
(1)
2. A compound of claim 1 in the form of an alkali metal salt, an amine salt or an acid addition salt.
3. A compound of claim 1 in the form of the paroxetine salt thereof.
4. A compound of claim 1 in the form of the hydrochloride salt thereof.
5. A solid blend of a compound according to any preceding claim and paroxetine hydrochloride.
6. A process for preparing a compound according to any preceding claim, which comprises reacting paroxetine in solution with maleic acid.
7. A process for preparing a blend of claim 5 which comprises treating a compound of claim 3 with hydrochloric acid.
8. A method of treating the Disorders which comprises administering to a patient in need thereof an effective amount of a compound according to any one of claims 1 to 5 or prepared using the process of claim 6 or 7.
9. A pharmaceutical composition for use in the treatment and/or prevention of any one or more of the Disorders which comprises a compound according to any one of claims 1 to 5 or prepared using the process of claim 6 or 7, together with a pharmaceutically acceptable carrier.
EP99961195A 1998-12-11 1999-12-10 Derivative of paroxetine Withdrawn EP1137646A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9827431.9A GB9827431D0 (en) 1998-12-11 1998-12-11 Novel compound
GB9827431 1998-12-11
PCT/GB1999/004176 WO2000035910A1 (en) 1998-12-11 1999-12-10 Derivative of paroxetine

Publications (1)

Publication Number Publication Date
EP1137646A1 true EP1137646A1 (en) 2001-10-04

Family

ID=10844142

Family Applications (1)

Application Number Title Priority Date Filing Date
EP99961195A Withdrawn EP1137646A1 (en) 1998-12-11 1999-12-10 Derivative of paroxetine

Country Status (5)

Country Link
EP (1) EP1137646A1 (en)
JP (1) JP2002532494A (en)
AU (1) AU1788800A (en)
GB (1) GB9827431D0 (en)
WO (1) WO2000035910A1 (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002053538A1 (en) 2000-12-29 2002-07-11 Pfizer Limited Amlodipine fumarate
AT5874U1 (en) 2000-12-29 2003-01-27 Bioorg Bv PHARMACEUTICAL PREPARATIONS CONTAINING AMLODIPINMALEAT
BR0116552A (en) 2000-12-29 2004-02-03 Pfizer Ltd Amlodipine hemi maleate, process, method for the treatment or prevention of angina or hypertension, pharmaceutical composition for use in the treatment and / or of angina or hypertension
GB2371862B (en) 2000-12-29 2004-07-14 Bioorg Bv Reference standards for determining the purity or stability of amlodipine maleate and processes therefor
DE60112305T2 (en) 2000-12-29 2006-05-24 Pfizer Ltd., Sandwich PROCESS FOR PREPARING AMLODIPINMALEAT
GB2372036B (en) 2000-12-29 2004-05-19 Bioorg Bv Aspartate derivative of amlodipine
MXPA03005882A (en) 2000-12-29 2005-04-19 Pfizer Ltd Amide derivative of amlodipine.
WO2002053541A1 (en) 2000-12-29 2002-07-11 Pfizer Limited Amide derivative of amlodipine
US7335380B2 (en) 2000-12-29 2008-02-26 Synthon Ip Inc. Amlodipine free base
US6653481B2 (en) 2000-12-29 2003-11-25 Synthon Bv Process for making amlodipine

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8430581D0 (en) * 1984-12-04 1985-01-09 Ferrosan As Treatment
AU3108097A (en) * 1997-06-10 1998-12-30 Synthon B.V. 4-phenylpiperidine compounds
JP2002505254A (en) * 1998-02-06 2002-02-19 スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー Paroxetine salt
EP1073652A1 (en) * 1998-04-09 2001-02-07 Smithkline Beecham Plc Paroxetine maleate

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO0035910A1 *

Also Published As

Publication number Publication date
GB9827431D0 (en) 1999-02-03
JP2002532494A (en) 2002-10-02
AU1788800A (en) 2000-07-03
WO2000035910A1 (en) 2000-06-22

Similar Documents

Publication Publication Date Title
CA2782517A1 (en) Polymorphic forms of 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoylbenzofuran-5-yl) piperazine hydrochloride
EP1078925A1 (en) 4-Phenylpiperidine compounds
EP1870405A1 (en) Carbonylated (Aza)cyclohexanes as dopamine D3 receptor ligands
WO1994013291A1 (en) Use of aryloxyalkyl substituted cyclic amines as calcium channel antagonists and new phenyloxyalkyl piperidin derivatives
EP1137646A1 (en) Derivative of paroxetine
WO2000035873A1 (en) Process for preparation of paroxetine maleate
CA2164296C (en) Heterocyclic chemistry
EP2072510A1 (en) Crystalline form of azelastine
SK13622000A3 (en) Crystalline form of paroxetine
EP1155016A1 (en) Process for the production of paroxetine hydrochloride acetone solvate
US20020137938A1 (en) Novel process
WO2001014335A1 (en) Process for preparation of paroxetin intermediate
WO2001012623A1 (en) Process for the preparation of paroxetine hydrochloride
EP1133492A1 (en) Process for the preparation of paroxetine hydrochloride
WO2001025201A1 (en) Process for the preparation of paroxetin intermediate
EP1140910A1 (en) Process for the preparation of an acetate salt of paroxetine or paroxetine analogues
WO2000078752A1 (en) Process for the production of paroxetine hydrochloride
US20010008940A1 (en) Novel process
JP3113447B2 (en) Aminocarboxylic acid derivatives, their production and use
WO2000039122A1 (en) Process for the preparation of an acetate salt of paroxetine or paroxetine analogues
WO2000032596A1 (en) Amine salts of paroxetine
WO2001017966A1 (en) Process for the preparation of 1-methyl-3-carbomethoxy-4-(4'-fluorophenyl)-piperidine
WO2001025202A1 (en) Process for the preparation of paroxetine intermediate
WO2000039123A1 (en) Process for the preparation of an acetate salt of paroxetine or paroxetine analogues
CZ20003343A3 (en) Crystalline form of paroxetine

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20010702

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

AX Request for extension of the european patent

Free format text: AL;LT;LV;MK;RO;SI

17Q First examination report despatched

Effective date: 20020111

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20020522